FIB-4 Index for Liver Fibrosis Calculator


Estimate the risk of advanced liver fibrosis from routine blood tests.

Enter the values and click Calculate.

Ange dina värden:
years
U/L
U/L
Resultat:

About this calculator

FIB-4 was developed in people with HIV and hepatitis C and is now widely used to screen for advanced fibrosis in fatty liver disease and other chronic liver conditions.

What you need

  • Age in years.
  • AST and ALT in U/L from a liver panel; typical values are under about 40 U/L.
  • Platelet count in x10^9/L, the same number as x10^3/microlitre; typical is 150 to 400.

Formula

FIB-4 = (age in years x AST in U/L) / (platelet count in 10⁹/L x square root of ALT in U/L).

Cut-offs

The original low cut-off is 1.30 and the high cut-off is 2.67. For people aged 65 or older a low cut-off of 2.0 is suggested because the index rises with age.

How to read the result

Below 1.30, advanced fibrosis is unlikely and many patients need no further fibrosis testing. Between 1.30 and 2.67 the index is indeterminate, and an elastography scan or a second marker usually follows. Above 2.67, advanced fibrosis is likely and specialist assessment is warranted. At age 65 or older the low cut-off shifts to 2.0 because age itself inflates the index.

Worked example

Age 50, AST 40, ALT 36, platelets 200: 50 x 40 / (200 x 6) = 1.67 (indeterminate).

Common mistakes

  • Using the index in acute hepatitis, where a sky-high AST breaks the assumptions.
  • Applying adult cut-offs under 35 or over 65 without the age adjustment.
  • Entering platelets in x10^3/microlitre thinking it is a different unit; it is the same number as x10^9/L.

Limitations

Less accurate under 35 and over 65, and in acute liver injury, hematologic disease, or when the platelet count is affected by other causes.

Frequently asked questions

Does FIB-4 diagnose fibrosis?

It screens. A high result usually leads to elastography or biopsy for confirmation; a low result is used to rule advanced disease out.

Why is age in the formula?

It was the strongest demographic predictor in the derivation cohort, but it is also why the index overcalls fibrosis in older patients unless the cut-off is adjusted.

Reference

  • Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-1325. doi:10.1002/hep.21178
  • McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112(5):740-751.

Disclaimer. Medical information only. This calculator is an educational aid for clinicians and students. It does not give medical advice, diagnosis or treatment, and it does not replace clinical judgment. Check results against the original source and local protocols before using them in patient care.